Follow
Giampaolo Merlini
Giampaolo Merlini
University of Pavia, Policlinico San Matteo
Verified email at unipv.it
Title
Cited by
Cited by
Year
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
49282014
International uniform response criteria for multiple myeloma
BGM Durie, JL Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, ...
Leukemia 20 (9), 1467-1473, 2006
34332006
Molecular mechanisms of amyloidosis
G Merlini, V Bellotti
New England Journal of Medicine 349 (6), 583-596, 2003
23942003
Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy
MS Maurer, JH Schwartz, B Gundapaneni, PM Elliott, G Merlini, ...
New England Journal of Medicine 379 (11), 1007-1016, 2018
19302018
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy, A Dispenzieri, ...
Circulation 133 (24), 2404-2412, 2016
16542016
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International …
MA Gertz, R Comenzo, RH Falk, JP Fermand, BP Hazenberg, ...
American journal of hematology 79 (4), 319-328, 2005
15252005
Inotersen treatment for patients with hereditary transthyretin amyloidosis
MD Benson, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, ...
New England Journal of Medicine 379 (1), 22-31, 2018
12102018
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hájek, ...
Leukemia 23 (2), 215-224, 2009
10472009
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and …
RA Kyle, BGM Durie, SV Rajkumar, O Landgren, J Bladé, G Merlini, ...
Leukemia 24 (6), 1121-1127, 2010
10102010
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
10062012
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes
G Palladini, A Dispenzieri, MA Gertz, S Kumar, A Wechalekar, ...
J Clin Oncol 30 (36), 4541-4549, 2012
9162012
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types
C Rapezzi, G Merlini, CC Quarta, L Riva, S Longhi, O Leone, F Salvi, ...
Circulation 120 (13), 1203-1212, 2009
8422009
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial
JL Berk, OB Suhr, L Obici, Y Sekijima, SR Zeldenrust, T Yamashita, ...
Jama 310 (24), 2658-2667, 2013
7162013
Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines
JD Sipe, MD Benson, JN Buxbaum, S Ikeda, G Merlini, MJM Saraiva, ...
Amyloid 23 (4), 209-213, 2016
6902016
Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis
JD Sipe, MD Benson, JN Buxbaum, S Ikeda, G Merlini, MJM Saraiva, ...
Amyloid 21 (4), 221-224, 2014
6302014
Amyloidosis: pathogenesis and new therapeutic options
G Merlini, DC Seldin, MA Gertz
Journal of Clinical Oncology 29 (14), 1924, 2011
6302011
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of …
S Dorbala, Y Ando, S Bokhari, A Dispenzieri, RH Falk, VA Ferrari, ...
Journal of Nuclear Cardiology 26, 2065-2123, 2019
609*2019
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
P Garcia-Pavia, C Rapezzi, Y Adler, M Arad, C Basso, A Brucato, ...
European heart journal 42 (16), 1554-1568, 2021
6022021
Serum N-terminal pro–brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
G Palladini, C Campana, C Klersy, A Balduini, G Vadacca, V Perfetti, ...
Circulation 107 (19), 2440-2445, 2003
5952003
Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee
MD Benson, JN Buxbaum, DS Eisenberg, G Merlini, MJM Saraiva, ...
Amyloid 25 (4), 215-219, 2018
5772018
The system can't perform the operation now. Try again later.
Articles 1–20